期刊文献+

骨保护素不同层面对内皮细胞的影响 被引量:2

Effect of osteoprotegerin on endothelial cells
下载PDF
导出
摘要 目的:观察骨保护素(OPG)作为始动因素对人内皮细胞的数量变化及内皮型一氧化氮合酶(endothelial nitric oxide synthase,eNOS)和一氧化氮(NO)产生的影响。方法:常规培养永生化的人内皮细胞,以不同浓度(0、0.5、1.0、2.0、4.0、6.0、8.0、10.0及100.0 ng/ml,共9组)的OPG作用细胞48 h后,用细胞计数试剂盒-8(cell count kit,CCK-8)来检测细胞的数量及NO检测试剂盒检测NO的产量。用免疫细胞化学染色法检测eNOS蛋白表达的水平,实时定量PCR检测eNOS基因的定量表达。结果:与对照组的细胞数(0.759±0.067)相比,8.0 ng/ml OPG组的细胞数为(1.091±0.200),P<0.05,10.0 ng/ml OPG组的细胞数为(1.103±0.152)及100.0 ng/ml OPG组的细胞数为(1.231±0.192),均P<0.01。8.0 ng/ml OPG组NO生成量为(102.224±0.612)μmol/L(P<0.05),10.0 ng/ml OPG组NO生成量为(117.183±0.552)μmol/L和100.0 ng/ml OPG组NO生成量为(128.216±0.492)μmol/L(均P<0.01)。同时eNOS蛋白及eNOS mRNA的表达量在6.0 ng/ml、8.0 ng/ml、10.0 ng/ml及100.0 ng/ml OPG组均显著地呈浓度依赖性增加(均P<0.01)。结论:OPG具有促进内皮细胞增殖效应,可能在抗动脉粥样硬化过程中有一定意义,且与浓度梯度呈明显的正相关。 AIM:To observe the effects of osteoprotegerin (OPG) as an initiating factor on the changes in the number of endothelial cells and on nitric oxide synthase (eNOS) and nitric oxide (NO). METHODS: Immortalized human endothelial cells were conventionally cultured and then treated with different concentrations of OPG (0, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0 and 100.0 ng/ml, total nine groups) for 48 h. Number of cells was detected with the cell count kit (CCK-8). Nitric oxide production was detected with nitric oxide detection kit, eNOS protein expressions was examined with immunocytochemical method and the level of eNOS mRNA was assayed with realtime quantitative PCR. RESULTS: Compared with the number (0.759±0.067) in control group, the number of endothelial cells gradually increased with the increase of OPG within the physiological concentration range. The increased number of cells in 8.0 ng/ml group and higher concentration groups were statistically significant, (1.091±0.200) in 8.0 ng/ml group (P〈0.05), (1.103±0.152) in 10.0 ng/ml group (P〈0.01) and (1.231±0.192) in 100.0 ng/ml group (P〈0.01). NO increased synchronously with the proliferation of endothelial cells and also reached statistical significance in 8.0 ng/ml and higher groups (102.224±0.612) in 8.0 ng/ml group (P〈0.05), (117.183 ± 0.552) in 10.0 ng/ml group (P〈0.01) and (128216±0.492) in 100.0 ng/ml group (P〈0.01). eNOS protein and mRNA expression in 6.0 ng/ml, 8.0 ng/ml, 100 ng/ml and 1000 ng/ml groups increased significantly in a concentration dependent manner (P〈0.01). CONCLUSION: OPG within the human physiological concentration range promotes endothelial cell proliferation. During the process of antiatherosclerosis, OPG may promote endothelial cell repair and the effect is positively correlated with the OPG concentration gradient.
出处 《心脏杂志》 CAS 2013年第6期649-653,共5页 Chinese Heart Journal
关键词 骨保护素 动脉粥样硬化 内皮细胞 osteoprotegerin atherosclerosis endothelial cell eNOS
  • 相关文献

参考文献15

  • 1Blair JM, Zheng Y, Dunstan CR. RANK ligand[ J]. Int J Biochem Cell Biol , 2007, 39(6):1077-1081.
  • 2Omland T, Ueland T, Jansson AM, et al. Circulating osteoprote- gerin levels and long-term prognosis in patients with acute coronary syndromes [ J ]. J Am Coll Cardiol, 2008, 51 ( 6 ) :627 - 633.
  • 3Anand DV, Lahiri A, Lim E, et al. The relationship between plas- ma osteoprotegerin levels and coronary artery calcification in uncom- plicated type 2 diabetic subjects[ J]. J Am Coll Cardiol, 2006, 47 (9) :1850 - 1857.
  • 4Anand DV, Lim E, Darko D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic con- trol and inflammatory/vascular calcification markers[ J]. J Am Coll Cardiol, 2007, 50(23) :2218 -2225.
  • 5Joshi MS, Ferguson TB Jr, Johnson FK, et al. Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells [J]. Proc Natl Acad Sci USA, 2007, 104(24) :9982 -9987.
  • 6Kuhhncordt PJ, Gyurko R, Hart F, et al. Accelerated atherosclero- sis aortic aneurysm formation, and ischemic heart disease in apoli- poprotein E/endothelial nitric oxide synthase double-knock-out mice [J]. Circulation, 2001, 104(4) :448 -454.
  • 7Lund DD, Faraci FM, Miller FJ, et al. Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from dia- betic rabbits [ J ]. Circulation, 2000, 101 (9) : 1027 - 1033.
  • 8Persson K, Sauma L, safholm A, et al. LDL and UV-oxidized LDL induce upregulation of iNOS and NO in unstimulated J774 macro- phages and HUVEC[J]. Apmis, 2009, 117( 1 ) :1 -9.
  • 9Asanuma Y, Chung CP, Oeser A, et al. Serum osteoprotegerin is increased and independently associated with coronary-artery athero- sclerosis in patients with rheumatoid arthritis [ J ]. Atherosclerosis, 2007, 195(2) :e135 - e141.
  • 10Sandberg WJ, Yndestand A, Oie E, et al. Enhanced T-ceU expres- sion of RANK ligand in acute coronary syndrome: possible role in plaque destabilization[ J]. Arterioscler Thromb Vasc Biol, 2006, 26 (4) :857 -863.

同被引文献32

  • 1Simonet WS, Lacey DL, Dunstan CR, et al.Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell.1997;89(2): 309-319.
  • 2Wang QP, Li XP, Wang M,et al.Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: an in ivo study. Endocrine. 2014 Mar 14. [E pub ahead of print].
  • 3Inanc M, Kaynar L, Enhos S, et al.Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid. Med Oncol.2014;31(3):837.
  • 4Wang B, Jin H, Zhu M,et al.Chondrocyte beta-catenin signaling regulates postnatal bone remodeling through modulation of osteoclast formation in a murine model. Arthritis Rheumatol. 2014; 66(1):107-120.
  • 5Klein-Nulend J, van Oers RF, Bakker AD,et al.Nitric oxide signaling in mechanical adaptation of bone. Osteoporos Int. 2014;25(5):1427-1437.
  • 6Buso G, Faggin E, Pauletto P, et al.Osteoprotegerin in Cardiovascular Disease:Ally or Enemy? Curr Pharm Des. 2014 Feb 12. [Epub ahead of print].
  • 7Kitaura H, Kimura K, Ishida M,et al.Effect of cytokines on osteoclast formation and bone resorption during mechanical force loading of the periodontal membrane. Scientific World J. 2014;2014:617032.
  • 8Wimalawansa SJ.Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Ann N Y Acad Sci. 2007;1117: 283-297.
  • 9Park EJ, Shen L, Sun D, et al.Inhibitory Effect of a Callophycin A Derivative on iNOS Expression via Inhibition of Akt in Lipopolysaccharide-Stimulated RAW 264.7 Cells. J Nat Prod. 2013. [Epub ahead of print].
  • 10Hakimi M, Hyhlik-Dürr A, von Au A, et al.The expression of glycophorin A and osteoprotegerin is locally increased in carotid atherosclerotic lesions of symptomatic compared to asymptomatic patients. Int J Mol Med.2013;32(2):331-338.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部